Henry ScheinHSIC
HSIC logo
Fair Value
US$97.56
Share price19 Aug
US$89.238.5% undervalued intrinsic discount
Loading
1Y30.63%
7D0.056%

HSIC: Earnings Momentum From Automation And E-Commerce Will Shape Outlook

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
25 Aug 24
Updated
19 Aug 26
Views
386
Not Invested

Last Update 19 Aug 26

Fair value Increased 11%

HSIC: Q2 Execution And Cost Controls Are Expected To Support Balanced Outlook

Henry Schein's updated analyst price target rises from about $88 to roughly $98, with analysts pointing to a strong Q2 showing, broad margin expansion, encouraging execution under the new CEO, and ongoing value creation efforts as key supports for higher revenue growth expectations and a higher future P/E assumption.

Analyst Commentary

Recent research on Henry Schein points to a cluster of higher price targets following the latest Q2 report, with most analysts framing the story around execution under the new CEO, margin trends, and the pace of the value creation program. For you as an investor, the key themes are how much confidence the market has in management delivering on its plan and what that could mean for valuation and growth expectations.

Bullish Takeaways

  • Bullish analysts highlight a strong Q2 report as support for higher price targets, which they view as improving confidence in Henry Schein's ability to execute under the new CEO.
  • Several reports point to broad based margin expansion in Q2 and earlier cost reduction efforts, which bullish analysts see as supportive of higher earnings power and potentially a higher P/E assumption.
  • The value creation initiatives, including expected contributions to the P&L and the potential for additional share buybacks, are seen by bullish analysts as not yet fully reflected in the stock valuation.
  • Some bullish analysts describe Henry Schein as a preferred pure play in dental markets and view current conditions in those markets as healthy enough to support ongoing growth in revenue and earnings estimates.

Bearish Takeaways

  • More cautious analysts describe Henry Schein as an execution dependent story and prefer to see stronger second half delivery before assigning a higher valuation multiple.
  • There is some hesitation around the new CEO's track record with public investors, with bearish analysts wanting more evidence that management can sustain the early execution improvements.
  • One firm maintains a Neutral stance and another a Market Perform rating with price targets that sit below the most bullish views, which suggests lingering uncertainty about how much upside the current value creation program can drive.
  • Some cautious commentary reflects concerns that the market may already be pricing in part of the expected margin and earnings benefits, leaving less room for a rerating if execution falls short of updated expectations.

What’s in the News for Henry Schein

  • Henry Schein reported Q2 2026 non GAAP diluted EPS of US$1.27, compared with Wall Street expectations of US$1.26, on revenue of US$3.46b, with management highlighting contributions from Global Distribution and Value Added Services segments. Source, company earnings reports summarized in recent news coverage.
  • The company reported a Q2 2026 non GAAP operating margin of 7.21%, supported by margin gains and higher adjusted EBITDA, reflecting the impact of cost saving programs and execution across Global Distribution, Specialty Products, and Technology segments. Source, recent earnings news.
  • Henry Schein raised full year 2026 adjusted EPS guidance to US$5.29 to US$5.39 and updated 2026 total sales growth expectations to 4.5% to 5.5%, compared with the previous range of 3% to 5%. Source, company guidance update and earnings coverage.
  • Between 29 March 2026 and 27 June 2026 the company repurchased 2,608,260 shares, representing 2.28% of shares, for US$200.03m and has completed total repurchases of 45,905,497 shares, representing 35.04%, for US$3.30b under the buyback that began on 13 December 2018. Source, company buyback tranche update.
  • Henry Schein entered a new partnership with GoTu Technology through Henry Schein Dental Recruitment Services to give dental practices broader access to GoTu’s staffing platform for hygienists, assistants, and associate dentists, aiming to address ongoing workforce shortages and support practice efficiency. Source, company partnership announcement.

Valuation Changes for Henry Schein

  • Fair Value has risen from about $88.07 to roughly $97.56, which reflects a moderate upward reset in what analysts see as justified pricing for Henry Schein.
  • Discount Rate has moved slightly higher from 7.30% to about 7.36%, which implies a marginally higher required return in current models.
  • Revenue Growth has been marked up from roughly 3.76% to about 4.19%, indicating a modestly stronger outlook for Henry Schein's top line in analyst assumptions.
  • Net Profit Margin is now modeled at about 4.30% compared with roughly 4.37% previously, which points to a small pullback in expected profitability levels.
  • Future P/E has increased from about 15.65x to roughly 17.17x, suggesting analysts are now using a higher valuation multiple for Henry Schein in their updated work.
0 viewsusers have viewed this narrative update

Key Takeaways

  • Focus on high-margin segments, digital transformation, and operational efficiencies is expected to boost margins and earnings growth.
  • Demographic shifts and industry consolidation are likely to drive sustained demand and enhance customer loyalty in key markets.
  • Margin pressures from competitive pricing, staffing constraints, regulatory hurdles, and execution risks could limit revenue growth and profitability despite stabilization efforts in key business areas.

Catalysts

About Henry Schein
    Provides health care products and services to office-based dental and medical practitioners, and alternate sites of care worldwide.
What are the underlying business or industry changes driving this perspective?
  • The company is experiencing strong growth in high-margin businesses such as Specialty Products, Technology, and private-label offerings, and expects over 50% of non-GAAP operating income to come from these segments-supporting structurally higher gross margins and likely driving earnings expansion.
  • Investments in digital workflow, AI solutions, and integrated cloud-based practice management platforms are accelerating recurring SaaS revenues and client retention, positioning Henry Schein to benefit from the ongoing digital transformation of healthcare, which should support both revenue growth and improved margins.
  • Henry Schein is actively pursuing operational efficiencies-including $100M+ cost savings run-rate by end of 2025 and further value creation initiatives led by KKR's Capstone-which are expected to lower operating expenses and drive net margin improvement from 2026 onward.
  • Continued expansion of the company's Home Solutions platform to meet increased demand for at-home healthcare, coupled with robust demographic drivers from an aging global population, are anticipated to support sustained volume growth in core distribution and specialty lines, providing a foundation for long-term revenue growth.
  • Dental and medical practice consolidation is increasing client reliance on integrated supply, technology, and value-added service partners like Henry Schein, enhancing share gains and customer stickiness across both the U.S. and international markets-with positive implications for top-line growth and earnings stability.
Henry Schein Earnings and Revenue Growth

Henry Schein Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Henry Schein's revenue will grow by 4.2% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 3.0% today to 4.3% in 3 years time.
  • Analysts expect earnings to reach $661.2 million (and earnings per share of $5.4) by about August 2029, up from $403.0 million today. The analysts are largely in agreement about this estimate.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 17.3x on those 2029 earnings, down from 24.7x today. This future PE is lower than the current PE for the US Healthcare industry at 25.0x.
  • Analysts expect the number of shares outstanding to decline by 5.33% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 7.36%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Persistent competitive pricing pressures, especially in key categories like gloves (where pricing remains very competitive and still below previous year levels), could continue to weigh on distribution gross margins, reducing profitability and potentially hindering earnings growth even as volume stabilizes.
  • Flat to modest dental patient traffic and ongoing staffing shortages (notably in hygienists and office support) are constraining underlying volume growth in the core dental business globally, which limits organic revenue expansion and exposes results to macroeconomic or reimbursement shocks in key markets.
  • Greater customer price sensitivity due to tariffs and the potential for large DSO/group customers to actively RFP portions of their business places greater bargaining power with customers, risking margin compression and slower top-line growth if Henry Schein cannot fully offset price concessions with its owned brands or value-added services.
  • International expansion, while producing some bright spots, faces country-specific regulatory challenges (e.g. recent law changes in France), currency volatility, and localized competition, all of which could restrict anticipated revenue diversification and net earnings contribution from outside the U.S.
  • The multi-year leadership transition and implementation of cost-saving/value creation initiatives with KKR/consulting partners carry significant execution risk; delays, integration hurdles, or cultural disruption could impair near-term efficiency gains, and if technology or AI investments lag or under-deliver, Henry Schein could lose share to more innovative or nimble competitors, pressuring long-term earnings growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of $97.56 for Henry Schein based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $112.0, and the most bearish reporting a price target of just $64.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $15.4 billion, earnings will come to $661.2 million, and it would be trading on a PE ratio of 17.3x, assuming you use a discount rate of 7.4%.
  • Given the current share price of $89.23, the analyst price target of $97.56 is 8.5% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Henry Schein?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Comments

0 comments

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value vs Share Price

US$97.56
vs US$89.238.5% undervalued intrinsic discount
PastFuture015b2015201820212024202620272029Revenue US$15.4bEarnings US$661.2m
4.2%
Revenue growth
4.3%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Henry Schein

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Good value with adequate balance sheet.

Market capUS$10.0b
PB3.1x
Estimated Growth4.0%
Dividend YieldN/A
Full analysis

CEO & management

Frederick Lowery
CEO
4.2yrs
CEO Tenure

Provides health care products and services to office-based dental and medical practitioners worldwide.